Radiation therapy for stage I and II testicular seminoma: changes in the treatment policy for the prescribed dose.
We set out to review treatment policy, survival rate and acute and late sequelae of histologically confirmed seminoma patients who underwent orchiectomy and radiation therapy. Thirty patients with testicular seminoma were investigated. The follow-up ranged from 1-20 years, with a median of 8.6 years. There were 23 patients with Stage I, six with Stage IIA and one with Stage IIB of the disease. All patients were treated with orchiectomy followed by iliac and paraaortic irradiation (median dose: 3900cGy for Stage I and 4000 cGy for Stage II patients). Up to 1986 the median total dose was 40Gy, and this dose was administered to sixteen patients. After that, fourteen patients received a total dose of 32Gy. For patients with Stage I and Stage II, 5- year disease-free survival rate was 100%. Twenty-three patients experienced certain acute reactions or side effects and all became well after radiation therapy; however, almost no patients showed severe late complications. In our study, radical orchiectomy and postoperative irradiation of iliac and paraaortic lymphaticus give good results for patients with Stage I and II testicular seminoma.